Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Dec 18:5:280.
doi: 10.3389/fphar.2014.00280. eCollection 2014.

Opioid receptor desensitization: mechanisms and its link to tolerance

Affiliations
Review

Opioid receptor desensitization: mechanisms and its link to tolerance

Stéphane Allouche et al. Front Pharmacol. .

Abstract

Opioid receptors (OR) are part of the class A of G-protein coupled receptors and the target of the opiates, the most powerful analgesic molecules used in clinic. During a protracted use, a tolerance to analgesic effect develops resulting in a reduction of the effectiveness. So understanding mechanisms of tolerance is a great challenge and may help to find new strategies to tackle this side effect. This review will summarize receptor-related mechanisms that could underlie tolerance especially receptor desensitization. We will focus on the latest data obtained on molecular mechanisms involved in opioid receptor desensitization: phosphorylation, receptor uncoupling, internalization, and post-endocytic fate of the receptor.

Keywords: biased signaling; desensitization; opioid receptors; receptor trafficking; tolerance mechanisms.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(A) Phosphorylation sites of MOR. The cluster 354TSST357: phosphorylation both by DAMGO and morphine (Lau et al., 2011). The S356 (equivalent to Ser358 in human) is phosphorylated by DAMGO (Moulédous et al., 2012), S356 and T357 are phosphorylated both by DAMGO and morphine (Chen et al., 2013). The S363 (equivalent to S365 in human) is phosphorylated in the absence of agonist (El Kouhen et al., ; Lau et al., ; Moulédous et al., ; Chen et al., 2013). PKC was demonstrated to phosphorylate S363 (Chen et al., ; Illing et al., 2014). The T370 (equivalent to T372 in human) is phosphorylated in the absence of agonist (Moulédous et al., ; Chen et al., 2013). A decrease of phosphorylation level is observed upon DAMGO and 1Dme (a neuropeptide FF analog) exposure (Moulédous et al., 2012). PKC (Illing et al., 2014) and CaMKII (Chen et al., 2013) phophorylate T370. DAMGO, morphine and etonitazene increase phosphorylation at T370 (Doll et al., ; Lau et al., 2011). DAMGO-mediated phosphorylation at this residue is ultra-rapid (20 s) (Just et al., 2013) and involves GRK2 and 3 (Doll et al., 2012) but not PKC (Illing et al., 2014). The cluster 375STANT379 displays higher level of phosphorylation upon DAMGO compared to morphine (Lau et al., 2011). S375 or T376 (equivalent to S377 and T378 in human) are phosphorylated upon DAMGO and 1Dme (Moulédous et al., 2012), DAMGO, etonitazene, and morphine (Doll et al., 2011). S375 is considered as the major phosphorylation site as it is rapidly phosphorylated (20 s) upon DAMGO (Just et al., 2013). This agonist-mediated phosphorylation does not implicate PKC (Illing et al., 2014) but rather GRK2 (Chen et al., 2013) or GRK2 and 3 (Doll et al., 2012) upon DAMGO exposure, and GRK5 and to a lesser extent GRK3 upon morphine treatment (Doll et al., 2012). T376 (equivalent to T378 in human) is phosphorylated upon DAMGO and 1Dme (Moulédous et al., 2012), by GRK2 and 3 upon DAMGO exposure but it is considered as a late phosphorylation site (20 min) (Just et al., 2013). T379 is also phosphorylated upon DAMGO exposure after 1 min and required the GRK3 (Just et al., 2013). Y166 (Clayton et al., 2010) and Y336 (Zhang et al., 2009) are phosphorylated by Src. (B) Phosphorylation sites of DOR. S344 phosphorylation is mediated by a PKC but is not increased by DPDPE (Xiang et al., 2001). S358 and S363 (Guo et al., ; Kouhen et al., 2000) are the two major sites of phosphorylation mediated by GRK2 upon DPDPE exposure. Deltorphin II and morphine are also able to increase phosphorylation at S363 (Navratilova et al., 2005). T361 is phosphorylated by DPDPE but after S358 and S363 phosphorylation (Guo et al., ; Kouhen et al., 2000). T161 is phosphorylated by CDK5 in the absence and in the presence of chronic morphine exposure (Xie et al., 2009). Y318 is phosphorylated by Src upon DTLET exposure (Kramer et al., 2000b). (C) Phosphorylation sites of KOR. Phosphorylation of S369 (rKOR) is mediated by GRK2 (Mclaughlin et al., 2003) and 3 (Mclaughlin et al., 2004) upon U50488 exposure. In hKOR, S358 is phosphorylated by GRK2 when activated by U50488 (Li et al., 2002).
Figure 2
Figure 2
Schematic illustration of mechanisms involved in opioid receptor desensitization by biased agonists. (A) MOR are differentially phosphorylated by different kinases upon either DAMGO or morphine exposure (Doll et al., 2011). This results in binding of arrestins to MOR upon DAMGO while this interaction is weakly detectable for morphine when a GRK is over-expressed (Groer et al., 2007). In such conditions, acute DAMGO exposure promotes G protein uncoupling from MOR while morphine does not (Whistler and Von Zastrow, 1998). However, MOR phosphorylation at S375 induced by morphine is able to promote desensitization but not internalization (Schulz et al., 2004). Some reports rather suggest that under morphine exposure, MOR is not desensitized and this continuous signaling promotes tolerance (Finn and Whistler, 2001). Even if it's now well-admitted that morphine is able to promote MOR internalization (Haberstock-Debic et al., ; Nowoczyn et al., 2013), DAMGO induces a stronger internalization compared to morphine (Whistler and Von Zastrow, ; Schulz et al., 2004). MOR is dephosphorylated by phosphatase proteins (Doll et al., 2012) then undergoes an active recycling (Tanowitz and Von Zastrow, 2003). Other proteins such as arrestins, dynamin, or GRK could participate MOR trafficking (Dang et al., 2011). In contrast, as morphine is a poor inducer of MOR internalization, receptor is maintained in a phosphorylation state at S375 for longer time compared to DAMGO. (B) Different kinases are involved in the regulation of hDOR (Marie et al., 2008): GRK2 plays a major role in receptor phosphorylation on S363 upon DPDPE and etorphine while other kinases are also implicated. Etorphine-induced desensitization requires arrestins but not receptor internalization. In contrast, an arrestin is involved in hDOR internalization but not desensitization upon DPDPE (Aguila et al., 2012). Once sequestrated by etorphine, hDOR is dephosphorylated and recycled back to the cell surface (Hasbi et al., ; Marie et al., 2003b) while upon DPDPE exposure, the receptor is mainly targeted to lysosomes for degradation (Marie et al., 2003b) probably by a mechanism involving GASP (Whistler et al., 2002).

References

    1. Abbadie C., Pan Y. X., Pasternak G. W. (2004). Immunohistochemical study of the expression of exon11-containing mu opioid receptor variants in mouse brain. Neuroscience 127, 419–430. 10.1016/j.neuroscience.2004.03.033 - DOI - PubMed
    1. Aguila B., Coulbault L., Boulouard M., Leveille F., Davis A., Toth G., et al. . (2007). In vitro and in vivo pharmacological profile of UFP-512, a novel selective delta-opioid receptor agonist; correlations between desensitization and tolerance. Br. J. Pharmacol. 152, 1312–1324. 10.1038/sj.bjp.0707497 - DOI - PMC - PubMed
    1. Aguila B., Coulbault L., Davis A., Marie N., Hasbi A., Le Bras F., et al. . (2012). ßarrestin1-biased agonism at human delta-opioid receptor by peptidic and alkaloid ligands. Cell Signal 24, 699–707. 10.1016/j.cellsig.2011.10.018 - DOI - PMC - PubMed
    1. Allouche S., Polastron J., Hasbi A., Homburger V., Jauzac P. (1999a). Differential G-protein activation by alkaloid and peptide opioid agonists in the human neuroblastoma cell line SK-N-BE. Biochem. J. 342 (Pt 1), 71–78. 10.1042/0264-6021:3420071 - DOI - PMC - PubMed
    1. Allouche S., Roussel M., Marie N., Jauzac P. (1999b). Differential desensitization of human delta-opioid receptors by peptide and alkaloid agonists. Eur. J. Pharmacol. 371, 235–240. 10.1016/S0014-2999(99)00180-6 - DOI - PubMed